NEW YORK (GenomeWeb) – NeoGenomics today reported a 3 percent year-over-year rise in revenues for the first quarter, while clinical testing revenues grew 4 percent.

For the three months ended March 31, the Fort Myers, Florida-based cancer genetic testing firm recorded $61.7 million in total revenues, slightly above the consensus Wall Street estimate of $61.4 million, and up from $59.7 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.